Company Overview

Enhabit, Inc. is a U.S.-based home health and hospice services provider operating within the post-acute healthcare industry. The company delivers skilled home health services and hospice care to patients, primarily serving Medicare beneficiaries, as well as Medicare Advantage and select commercial payors. Its core offerings include skilled nursing, physical, occupational and speech therapy, medical social work, and hospice care focused on symptom management and end-of-life support. Enhabit’s revenue is largely driven by episodic and visit-based reimbursement models under government healthcare programs.

Enhabit is positioned as a pure-play home-based care company, emphasizing clinical quality, localized care delivery, and compliance-driven operations in a highly regulated environment. The company was spun off from Encompass Health Corporation in July 2022, establishing itself as an independent, publicly traded entity. Its strategic focus since the separation has been operational stabilization, margin improvement, and disciplined growth within its existing footprint rather than aggressive expansion.

Business Operations

Enhabit operates through two primary business segments: Home Health and Hospice, both of which are reportable segments. The Home Health segment provides skilled in-home clinical services to patients recovering from illness, injury, or surgery, while the Hospice segment delivers interdisciplinary end-of-life care focused on comfort and quality of life. The company generates revenue primarily through reimbursements from Medicare, Medicare Advantage, Medicaid, and commercial insurers, with Medicare representing the majority of revenue.

Operations are conducted through hundreds of local care locations across the United States under the Enhabit Home Health & Hospice brand. Enhabit does not rely on proprietary medical devices but emphasizes standardized clinical protocols, workforce management systems, and compliance infrastructure. The company operates independently, with no disclosed material joint ventures, and relies on organic development and de novo locations rather than large-scale acquisitions.

Strategic Position & Investments

Enhabit’s strategic direction centers on operational efficiency, clinical outcomes, and reimbursement optimization, particularly in response to evolving Medicare payment models such as PDGM and hospice rate updates. Management has prioritized cost controls, clinician retention, and branch-level performance improvement to stabilize margins following industry-wide reimbursement pressure and labor cost inflation.

Since becoming an independent company, Enhabit has pursued limited acquisition activity, focusing instead on internal investments in workforce training, clinical quality programs, and operational systems. The company remains focused on the home-based care sector, which benefits from long-term demographic trends such as aging populations and preference for in-home treatment. Public disclosures do not indicate material investments in emerging healthcare technologies beyond standard care delivery and operational platforms.

Geographic Footprint

Enhabit operates exclusively within the United States, with a broad presence across multiple states and regions, including the Southeast, Midwest, Southwest, and Western U.S. markets. Its headquarters is located in Dallas, Texas, serving as the central hub for corporate management, compliance, and administrative functions.

The company’s geographic strategy emphasizes density within existing markets to improve referral relationships and operational leverage rather than international expansion. Enhabit does not have international operations or foreign subsidiaries, and its operational influence is confined to domestic healthcare markets regulated by U.S. federal and state authorities.

Leadership & Governance

Enhabit is led by an executive team with experience in post-acute and home-based healthcare, many of whom previously held leadership roles within Encompass Health prior to the spin-off. The leadership philosophy emphasizes local clinical autonomy supported by centralized governance, regulatory compliance, and disciplined capital allocation.

Key executives include:

• Barbara Jacobsmeyer – President and Chief Executive Officer
• Derek Wright – Chief Financial Officer
• Crissy Carlisle – Chief Operating Officer
• Donna Shelton – Chief Human Resources Officer
• Kevin Lusk – Chief Accounting Officer

The company is governed by an independent board of directors, consistent with public company governance standards, with oversight of strategy, risk management, and executive compensation.